Loading
Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.
Sentinel lymph node biopsy injects a tracer (radiocolloid, blue dye, ICG, or magnetic particles) at the tumour to identify the first draining node, which is removed and examined instead of clearing the whole nodal basin. It is standard in breast cancer and melanoma and replaced full node dissection for most patients after Z0011 and AMAROS showed that omitting completion dissection did not compromise outcomes. The main benefit is avoiding lymphoedema from full dissection. It is now being omitted entirely in low-risk breast cancer (SOUND, INSEMA trials), an example of surgical de-escalation driven by better systemic therapy and imaging. False negatives occur in roughly 5-10% of cases, which is the accepted trade-off. The simple version is that surgeons check the one node most likely to harbour spread rather than removing them all.
Tracer (radiocolloid, blue dye, ICG, magnetic) injected at tumour identifies draining node.
Hexaminolevulinate makes bladder tumours fluoresce red under blue light so the urologist can see and remove flat and tiny cancers that white-light cystoscopy misses.
Technetium sulfur colloid is the radioactive tracer injected around a breast cancer or melanoma before surgery so the surgeon can find the first lymph node the tumour drains to and remove only that node instead of the whole basin.
The purpose-built tracer for sentinel lymph node mapping in breast cancer, melanoma and oral cancer, replacing off-label sulfur colloid.
Query for this technology: (TITLE:"sentinel lymph node biopsy" OR ABSTRACT:"sentinel lymph node biopsy" OR TITLE:"sentinel node" OR ABSTRACT:"sentinel node") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sentinel lymph node biopsy, not a curated reading list.
Shares FIRES & SENTOR (sentinel node mapping), Prizes for unpatentable surgical and radiotherapy techniques proven in trials, Keio University Hospital, European Society of Surgical Oncology and the tag precision.
Shares Targeted axillary dissection (MD Anderson prospective study), European Society of Surgical Oncology, Society of Surgical Oncology, Surgical robots: da Vinci, Hugo, Versius and single-port systems and the tag precision.
Shares Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Ductal carcinoma in situ (DCIS), Breast cancer (all types), Triple-negative breast cancer (TNBC) and the tag precision.
Shares Lightpoint Medical, Gamma probes, handheld gamma cameras and dose calibrators, Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Precision roadmap: margins measured in millimetres → tests that find a target → doses fitted to the person → precision that changes outcomes and the tag precision.
Shares Payer-funded trials that omit surgery or radiotherapy in low-risk patients, AMAROS (EORTC 10981-22023), SENOMAC, Lip cancer and the tag precision.
Shares Early cervical cancer and fertility-sparing surgery, POLE-ultramutated endometrial cancer, High-risk early HR-positive breast cancer, Early HER2-positive breast cancer and the tag precision.
Shares Precision roadmap: margins measured in millimetres → tests that find a target → doses fitted to the person → precision that changes outcomes, Head and neck squamous cell carcinoma, Breast cancer (all types) and the tag precision.
Shares Precision roadmap: margins measured in millimetres → tests that find a target → doses fitted to the person → precision that changes outcomes, Cutaneous squamous cell carcinoma, Breast cancer (all types) and the tag precision.